 PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. BridgeBio Nasdaq: BBIO and Eidos Therapeutics, Inc. Eidos Nasdaq: EIDX today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBios acquisition of all of the outstanding shares of Eidos common stock that BridgeBio does not already own. The merger is expected to close on or about January 26, 2021, subject to the satisfaction or waiver of other conditions to closing. 